

Anti-CD20 Antibody (Rituximab Biosimilar)

Cat. No. AB86


Description	
Reactivities	Human
Target	CD20
Isotype	Human IgG1-Kappa
Conjugation	Unconjugated
ExpressSystem	HEK293
Applications	ELISA/SPR/BLI
MolecularWeight	49.2 kDa and 23.1 kDa.
Recommended Dilution Buffer	PBS (pH 7.4), contains no stabilizers or preservatives.
Purification	protein A
Sterility	0.2 µM filtered
Endotoxin	Less than 1 EU per µg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE
	> 95% as determined by HPLC

Formulation and Storage	
Formulation	PBS, 10% glycerol (pH 7.4)
Storage	Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background	
B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity. CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases.	

Assay Data


Bis-Tris PAGE



Rituximab Biosimilar on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC

Assay Data




The purity of Rituximab Biosimilar is greater than 95% as determined by SEC-HPLC.

Assay Data

ELISA Data

Rituximab Biosimilar ELISA
0.5µg Human CD20 VLP Per Well



Immobilized Human CD20 VLP at 5µg/ml (100µl/Well) on plate on the plate. Dose response curve for Rituximab Biosimilar with the EC50 of 8.6ng/ml determined by ELISA